Nasdaq Biotechnology Ishares (IBB) 341.75 $IBB An Inside

New Post Public Reply Private Reply Replies (0) Message Board

Aug 26, 2015 at 10:17 PM

Nasdaq Biotechnology Ishares (IBB) 341.75 $IBB

An Inside Look at Biotech Investor Pros Dealing With Market Meltdown
at The Street - Tue Aug 25, 6:38AM CDT
Last night, I exchanged emails with a number of investors who run dedicated health care funds. I wanted to know how they navigated Monday's market selloff.
GILD: 106.96 (+4.40), IBB: 341.75 (+16.49), CELG: 119.23 (+6.53)

After Yesterday's Decline of 4.40%, iShares Nasdaq Biotechnology Index Offers Investors Better Value
Comtex SmarTrend(R) - Mon Aug 24, 4:59PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $284.16 to a high of $340.23. Yesterday, the shares fell 4.4%, which took the trading range below the 3-day low of $339.80 on volume of 4.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 341.75 (+16.49)

Watch for iShares Nasdaq Biotechnology Index to Potentially Rebound After Falling 4.40% Yesterday
Comtex SmarTrend(R) - Mon Aug 24, 4:59PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $284.16 to a high of $340.23. Yesterday, the shares fell 4.4%, which took the trading range below the 3-day low of $339.80 on volume of 4.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 341.75 (+16.49)

Crash Alert
Bill Bonner - Daily Reckoning - Mon Aug 24, 1:06PM CDT
This post Crash Alert appeared first on Daily Reckoning . Bill Bonner discusses the mounting evidence for a large, dramatic, and imminent market crash... The post Crash Alert appeared first on Daily Reckoning .
IBB: 341.75 (+16.49)

Biotech Stocks Recover From Early-Morning Flash Crash
at The Street - Mon Aug 24, 11:43AM CDT
The iShares Nasdaq Biotechnology Index (IBB), the most closely followed biotech sector index, is down less than 1% after a deep plunge at Monday's open.
VRTX: 130.11 (+8.94), GILD: 106.96 (+4.40), XBI: 218.99 (+10.78), IBB: 341.75 (+16.49), CELG: 119.23 (+6.53)

Bear Chart of the Day: iShares Nasdaq Biotechnology ETF Isn't Healthy
at The Street - Fri Aug 21, 1:15PM CDT
The exchange-traded fund will reach oversold levels if it falls to the $330-$335 area from the current $346.
IBB: 341.75 (+16.49)

Bear Chart of the Day: iShares Nasdaq Biotechnology ETF
at The Street - Fri Aug 21, 8:30AM CDT
Will we get a bullish play off a bearish chart?
IBB: 341.75 (+16.49)

'Fast Money' Recap: Why Fear Ruled the Markets
at The Street - Fri Aug 21, 4:00AM CDT
The trading panel discussed why investors let emotion overrule logic, whether to buy 'FANG' stocks and Hewlett-Packard earnings.
NFLX: 110.13 (+8.61), AMZN: 500.77 (+34.40), IBM: 146.70 (+5.74), FB: 87.19 (+4.19), M: 58.72 (+1.95), IBB: 341.75 (+16.49), DIS: 99.23 (+3.34), AMGN: 153.98 (+8.79), GOOGL: 659.74 (+47.27), IWM: 112.48 (+2.79), HPQ: 27.10 (+1.41)

SmarTrend Watching for Potential Rebound in Shares of iShares Nasdaq Biotechnology Index After 4.06% Loss
Comtex SmarTrend(R) - Thu Aug 20, 3:54PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $350.70 to a high of $364.85. Yesterday, the shares fell 4.1%, which took the trading range below the 3-day low of $360.06 on volume of 2.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 341.75 (+16.49)

'Fast Money' Recap: Building on a Housing Position
at The Street - Tue Aug 18, 4:00AM CDT
The trading panel looked at Tesla, oil and the rapidly improving housing sector.
DHI: 29.52 (+1.24), VLO: 58.85 (+1.24), TSLA: 224.84 (+4.81), HD: 115.93 (+4.96), RYL: 42.35 (+0.77), TSO: 91.76 (+3.08), XBI: 218.99 (+10.78), PHM: 19.82 (+0.91), ITB: 27.04 (+0.66), IBB: 341.75 (+16.49), IWM: 112.48 (+2.79), KBH: 13.94 (+0.32)

The Trader Daily: Starting with a Glass-Half-Full Approach
at The Street - Mon Aug 17, 6:30AM CDT
But failure to hold the 2082.50 figure likely reverses that.
EWX: 36.41 (+1.26), FCG: 6.00 (+0.20), XBI: 218.99 (+10.78), IBB: 341.75 (+16.49), SMH: 47.75 (+2.09), XME: 18.01 (+0.02), GDX: 13.04 (-0.63), XLE: 61.26 (+2.04)

Stocks Will Be More Volatile This Month; Twitter CEO Watch
at The Street - Fri Aug 14, 2:36PM CDT
CNBC's 'Fast Money' traders believe stocks will get more volatile this month, while SunTrust's Bob Peck says Jack Dorsey could be named CEO of Twitter as soon as next week.
USO: 12.77 (+0.04), UCO: 18.09 (+0.24), SPY: 194.46 (+7.19), QQQ: 103.03 (+4.94), XBI: 218.99 (+10.78), DIA: 162.66 (+6.17), IBB: 341.75 (+16.49), IWM: 112.48 (+2.79), TWTR: 25.03 (+0.65), TLT: 121.93 (-2.40)

Biotech Boom Over? 3 Health Care ETFs to Invest in Instead
Zacks Equity Research - Zacks Investment Research - Thu Aug 13, 11:58AM CDT
Since the hot biotech ETF space appears to go on a correction mode lately, investors can invest in these better-insulated health care ETFs.
IHF: 131.50 (+3.61), SBIO: 32.44 (+1.41), BBC: 30.36 (+0.86), PSCH: 69.63 (+1.78), XHS: 123.44 (+2.62), XBI: 218.99 (+10.78), IBB: 341.75 (+16.49)

Stocks & ETFs to Reflect Top Sales Growth
Zacks Equity Research - Zacks Investment Research - Wed Aug 12, 3:13PM CDT
These stocks saw the best sales growth (y/y) in Q2. Investors interested to tap these stocks can also play via ETF approach.
DHI: 29.52 (+1.24), LEN: 49.70 (+1.52), GILD: 106.96 (+4.40), XHB: 35.69 (+0.80), ITB: 27.04 (+0.66), IBB: 341.75 (+16.49), XLK: 39.60 (+1.90), BBH: 126.68 (+6.09), VGT: 100.54 (+4.78), AAPL: 109.69 (+5.95), IYW: 98.76 (+4.76)

Cramer -- Biogen Rally Could Boost Sector, Freeport-McMoRan Hopes for Rebound
at The Street - Mon Aug 10, 10:21AM CDT
The selloff in Biogen looks overdone, Cramer says. Freeport-McMoRan is shoring up its balance sheet and hoping for a turnaround.
BIIB: 298.25 (+16.51), FCX: 7.92 (-0.32), IBB: 341.75 (+16.49)

Trader's Notebook: Don't Catch Gold Fever (Yet)
at The Street - Fri Aug 07, 8:00AM CDT
Although natural gas ETFs were up Thursday and gold charts are showing some positive signs, the worst is far from over.
FCG: 6.00 (+0.20), XBI: 218.99 (+10.78), IBB: 341.75 (+16.49)

'Fast Money' Recap: Dipping Health Care, Rising Energy, Russell Index and Stock Volatility
at The Street - Fri Aug 07, 4:00AM CDT
The trading panel considers the downward swing in the health care sector and upward movement in energy. The panel also discusses the steep drop of SunEdison.
SUNE: 9.22 (+0.42), TSL: 8.52 (+0.03), IBB: 341.75 (+16.49), DIS: 99.23 (+3.34), TAN: 28.20 (+0.56), KORS: 41.07 (+1.68), IWM: 112.48 (+2.79), GDX: 13.04 (-0.63), SO: 43.61 (+1.11), AAPL: 109.69 (+5.95)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Veterans Transitioning to Real Estate with Scholarships

Tapping Military Skills for Civilian Gain Finding a new career after military service is a mountain of a task, but veterans now have a golden ticket into the real estate appraisal world. The Appraisal Institute's Next Mission Scholarship is throwing veterans a $1,000 life preserver to dive into a field where their military-honed skills already shine. The Power of a...

Paradigm Therapeutics: A Beacon in Rare Diseases

A Step Towards Recognition You know the old saying: innovation never sleeps. Well, Paradigm Therapeutics seems to have taken that to heart. The company's embarked on a peculiar yet promising journey with SD-101 (Zorblesia™), and here they are, basking in the glow of another nomination for the 2026 Prix Galien USA "Best Start-Up" award. It’s their second shot at this...

Think Tank Pushes for Bold Parkinson's Prevention Plan

A New Era for Parkinson's Disease Prevention The Parkinson's Foundation has rolled out its battle plan to take on Parkinson's disease from the ground up, shifting gears from managing symptoms to stopping the illness before it starts. It's about damn time, too. With the disease being the fastest-growing neurodegenerative disorder and impacting 10 million people worldwide,...

Celebree Gains Franchise Momentum: A New Frontier

The Climb: Celebree Schools on the Rise Here's a nugget in the franchise world that's causing a stir: Celebree School is making moves up the Franchise Times Top 400. When we're talking about a hop, skip, and jump through 84 spots since 2023, you can't help but notice. It's the third year in a row they're climbing this ladder, and it's making ripples. Franchise Expansion...

Home Buying: Unmasking All the Real Budget Costs

Home Buying: More Costs Than Meets the Eye Let's face it, buying a home is no stroll in the park. It's a tangled web of numbers and surprises that can leave even the savviest buyer in a daze. Thank goodness for articles like the one from HelloNation featuring Serena LoPiccolo-Smith, which make the invisible visible when it comes to the financial intricacies of home...

CMC Declares Dividend Amid Complex Outlook

Dividend's Not Just a Regular Check October 13, 2026, marks yet another dividend declaration by CMC. This time, they're dishing out $0.20 per share—a steady payday for loyal shareholders. That's 248 times in a row they've done this song and dance. Odds are, folks holding NYSE:CMC shares are giving the nod of approval, but it ain't just about cash; it's about stability...

Maven Pet's AI Paw-tnership: Changing Pet Care Landscape

AI in the World of Doggie Docs In today's tech-driven world, pet owners are turning to artificial intelligence like never before. Forget flipping through outdated dog-care books—nearly half of us are drilling ChatGPT for health tips on our four-legged pals. Yes, it seems we’re asking an AI about Rover's health more than some other major life decisions. But let's face...

Franco-Nevada's Q3 Results Loom: Investors Ready

Gearing Up: Franco-Nevada's Q3 Numbers on the Horizon You know the drill! Franco-Nevada's third quarter results won't just trickle in—they'll set the tone for the months ahead. Mark your calendar: November 11th after the market closes is the magic hour when you'll get the skinny on their Q3 performance. The next morning, bright and early at 8:00 AM ET, they'll hash it...

Coventry's Jacobs Joins European Life Settlement Execs

Neal Jacobs Steps Up in Life Settlements Coventry has added another feather to its cap with Neal Jacobs, their Senior Managing Director of Capital Markets, joining the Executive Committee of the European Life Settlement Association (ELSA). Elected at ELSA's Annual General Meeting on September 15, 2026, Jacobs brings a wealth of experience that promises to bolster the...

Omneky Outshines Competitors in AI Ad Scoring

Brewing a better ad with AI isn't just about the model you plug in—it's about the wizardry wrapping around it. Omneky's latest caper in the AI advertising game has snagged the spotlight, pulling a hearty 8.8 taste score on a recent TasteBench comparison. That's not a minor tweak, folks, but a whopping 1.2-point lead over the shadow-chasing curves of the next...